Skip to Main Content

Paper Details

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5â¿¿Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
J Am Heart Assoc
3
2023
Alirocumab, Patients
Author NameAffiliation
Deepak L BhattIcahn School of Medicine at Mount Sinai NY New York USA.
Robert A HarringtonStanford Center for Clinical Research, Department of Medicine Stanford University CA Stanford USA.
  • 1 - 2

Datasets

Release 1.2